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Rheumatoid arthritis (RA) is a common condition with a global 
prevalence of ~1%.[1] African-based prevalence studies are sparse 
with heterogeneous findings, currently suggesting a slightly lower 
frequency. However, further research is required to ascertain the 
prevalence of RA in Africa.[2,3] The disease is associated with decreased 
life expectancy and impaired quality of life, and places a significant 
financial burden on patients and society at large.[4] Numerous 
developments in the management of RA have recently emerged. Most 
notable is the importance of early aggressive management according 
to a ‘treat-to-target’ approach, and the introduction of biological 
disease-modifying antirheumatic drugs (bDMARDs).[5,6] These drugs 
are highly effective with regard to disease control, delaying clinical 
and radiological progression and joint destruction, and improving 
quality of life.[7]
South African (SA) guidelines for the management of RA were 
published in 2013.[6] Drafted by the South African Rheumatism and 
Arthritis Association, these guidelines were compiled in accordance 
with international standards of treatment. The guidelines advocate 
early use of conventional synthetic disease-modifying antirheumatic 
drugs (csDMARDs) and rapid escalation of therapy, with the goal of 
reaching a state of low disease activity (LDA) or preferably remission. 
The csDMARDs typically used include methotrexate, sulphasalazine, 
chloroquine (or hydroxychloroquine) and leflunomide.[6] Metho-
trexate remains the anchor of treatment with these agents, with 
other drugs being included by means of an add-on approach or 
sequential monotherapy.[8] According to these guidelines, patients 
should be considered for initiation on a biological agent if the disease 
is not controlled to target (LDA or remission) by 6 months despite 
adequate escalation in treatment.[6] Significant cost is involved in 
the procurement of biological agents, and the use of these drugs is 
therefore very limited in the public sector. Consequently, the vast 
majority of patients remain dependent on conventional agents.
Research has shown that the degree of disease control on traditional 
DMARDs varies significantly and depends on various factors, such 
as duration of disease and the scoring system used to determine 
disease activity. A study in Johannesburg comparing disease activity 
scores revealed that >60% of patients were in a state of either LDA 
or remission, with minimal variation between the scoring tools.[9] 
This finding was comparable to Turkish data.[10] In 2012, however, 
Hodkinson et al.[11] found that only 28.4% of patients with early RA 
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to poor control appear to be problems relating to dispensing of medication and inadequate escalation of therapy by doctors. Most of the 
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achieved LDA/remission after 12 months of traditional DMARDs, 
which was again comparable to other international data. Despite the 
impression of generally poor control of RA, data relating to the degree 
of disease control in SA are limited, and there are none for Free State 
Province. Numerous reports from patients and healthcare providers 
have suggested a lack of drug availability at peripheral pharmacies. 
As poor disease control has a profoundly negative impact, it is 
important to determine to what degree patients’ RA is controlled, and 
to elucidate any factors preventing control. Addressing these issues 
will assist with improvement in patient management, especially in 
this resource-limited setting where more advanced treatments are 
not readily available.
Objectives
To evaluate the degree of disease control of RA with conventional 
DMARDs in the rheumatology outpatient department of Universitas 
Academic Hospital in Bloemfontein, SA, and to determine the 
relative impact of various factors contributing to the prevention of 
disease control.
Methods
Study design and setting
This cross-sectional study was conducted in the rheumatology 
outpatient department of Universitas Academic Hospital during 
the arthritis clinics on Mondays and Thursdays where all patients 
with RA are seen. The department manages the majority of patients 
with RA in Bloemfontein’s public healthcare sector, as well as a large 
portion from the rest of the Free State and a number from Northern 
Cape Province. The department serves as the only rheumatology 
department in the Free State and Northern Cape provinces.
Participants
Participants deemed eligible for inclusion were patients with RA 
fulfilling the American College of Rheumatology/European League 
Against Rheumatism criteria of 2010 (as per the SA RA guidelines) 
who had been treated for at least 6 months, thus ensuring sufficient 
time for adequate escalation of therapy by the time of enrolment.[6] 
Patients were selected consecutively until a predetermined minimum 
of 150 participants were included. Patients on biological agents and 
those with inadequate or unclear information crucial to the primary 
or secondary objectives of the study were excluded from the study.
Data collection
Before each clinic, patient files were screened for participants 
eligible for enrolment. These patients were then handed information 
documents with a detailed description of the intended study and 
proceedings to follow. After discussing all aspects of the study with 
each patient, written informed consent was obtained. An information 
sheet and questionnaire were completed by the attending doctor or 
the researchers during consultations. A copy was kept in each source 
file to prevent rescreening of the same patient.
The following data were collected on the information sheets: 
(i) from the source file: basic demographic data, the Clinical Disease 
Activity Index (CDAI) score, what DMARDs the patient was taking 
at the time of the study, and the dosage; and (ii) what pharmacies the 
patient had attended each month (viz. 1st, 2nd and 3rd - 6th months), 
whether they were receiving all their DMARDs every month (and if 
not, which agents they had not received, and for what reason), and 
whether the patient was taking all the DMARDs received (and if 
not, whether this was due to compliance/insight problems, adverse 
drug reactions, or any other reason). Patients’ reasons for not taking 
all their medications were completed by ticking the relevant boxes. 
Additional space was provided for elaboration on unforeseen factors. 
Patients were requested pertinently to provide information with 
regard to taking of medication and reasons for not taking their 
medication as prescribed.
Disease control was assessed by means of the CDAI score, an 
internationally accepted composite scoring system comprising four 
parameters to determine overall disease activity, namely: (i) a 
swollen joint count; (ii) a tender joint count; (iii) the patient’s global 
assessment; and (iv) the doctor’s global assessment of the disease 
state.[7] As opposed to other validated scoring systems, the CDAI 
score was used in this study because it is the current standard of 
assessment used in this institution, and the accuracy is comparable to 
that of other validated disease activity scores.[9] The degree of disease 
control was grouped into four categories based on the patient’s CDAI 
score, namely: (i) ≤2.8 = remission; (ii) 2.9 - 10 = LDA; (iii) 11 - 22 = 
moderate disease activity; and (iv) >22 = high disease activity. A score 
falling within the categories of LDA or remission was considered to 
indicate disease control.
The minimal acceptable treatment for a patient with uncontrolled 
disease was considered to be at least three csDMARDs at optimally 
high doses, defined in this study as follows: methotrexate at least 
20 mg weekly, sulphasalazine at least 1 g twice daily, chloroquine at 
least 200 mg daily, and leflunomide at least 20 mg daily. In a situation 
where an adverse event caused by a DMARD was the only factor 
preventing further escalation of therapy, the treatment would still 
be deemed sufficient. In cases where the disease was not controlled 
despite the absence of any possible explanation for poor control, it 
was considered to be refractory to csDMARDs.
The data collected were transferred to a Microsoft Excel spreadsheet 
for analysis. The various factors identified as possible contributors 
to poor control were grouped as follows: (i) insufficient treatment 
for disease state; (ii) dispensing problems; (iii) adverse effects 
of medication; (iv) poor compliance/insight; (v) administrative 
problems; (vi) problems involving access/transport; and (vii) other 
unforeseen issues.
Statistical analysis
Data were analysed by the Department of Biostatistics of the 
University of the Free State using the Statistical Analysis System 
version 9.3 (SAS Institute, USA). Results were summarised using 
frequencies and percentages for categorical variables, and percentiles 
for numerical variables due to skew distributions.
Ethical considerations
Ethical approval was obtained from the Health Sciences Research 
Ethics Committee of the University of the Free State (ref. no. 
HSREC 108/2016) prior to data collection. Provincial permission 
was then granted by the Free State Department of Health (ref. no. 
FS_2016RP3_140). Written informed consent was obtained from all 
participants enrolled in the study.
Results
Data were collected from 169 participants over a period of 8 months. 
Of the 169 participants, 8 were excluded from data analysis, 6 on the 
basis of insufficiently completed information sheets and 2 due to 
current or planned pregnancy. The authors considered the latter to 
be a confounding factor in that pregnancy has an effect on disease 
control and pregnant patients cannot use certain DMARDs owing 
to teratogenic effects. Data analysis was performed on the remaining 
161 participants (Fig. 1).
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The study had a well-represented sample 
population, as shown by the demographic 
information set out in Table 1. The patients’ 
median age was 58 years (range 19 - 83). 
The majority of patients were female 
(n=138, 85.7%) and black African (n=131, 
81.4%). With regard to degree of disease 
control (Table 1), 34 (21.1%) were optimally 
controlled and only 5 (3.1%) were in 
remission. In contrast, 71 patients (44.1%) 
with high disease activity were identified.
Table 2 summarises the various factors 
reported by patients that may have 
contributed to poor disease control in 
the total study population, patients with 
an uncontrolled disease state, and patients 
in whom the disease was deemed to be 
controlled. In 21 (13.0%) of the total group 
of patients, no discernible cause for poor 
control was found, and these patients 
were considered to have disease that was 
refractory to csDMARDs.
Of the 34 patients with controlled RA, 
24 (70.6%) had no documented factors 
that might have impacted on their disease 
control, and 10 (29.4%) were controlled 
despite possible factors that might have 
resulted in poor control.
With regard to the dispensing of 
DMARDs, 159 of the participants (98.8%) 
reported receiving all of their medication 
for their first month of treatment, and 154 
(95.7%) received their medication from the 
Universitas Hospital pharmacy. As shown in 
Fig. 2, the number of patients receiving all of 
their DMARDs decreased over time. From 
the second month onwards, patients mainly 
received their medication from different 
healthcare facilities in the five districts of 
the Free State.
Discussion
The study revealed that disease control 
of RA at Universitas Academic Hospital 
is suboptimal compared with available 
national and international data, with other 
studies showing a degree of control ranging 
between 28% and 60%.[9-13] However, studies 
reporting control are limited and further 
research is required on provincial and 
national levels.
Poor control could be attributed to 
contributing factors such as inadequate 
escalation of treatment and problems 
with the dispensing system, resulting in 
lack of availability of medication, mainly at 
peripheral unit pharmacies.
A large proportion of patients seemed to 
be on inadequate treatment for their disease 
state. It should be noted, however, that 
common practice dictates that a practitioner 
would not escalate therapy until confirming 
that the patient is receiving all prescribed 
medication and adherence is ensured. Of 
the 72 patients deemed to be on inadequate 
medication for their disease state, 33 (45.8%) 
experienced concomitant dispensing 
issues. It could therefore be accepted that 
inadequate escalation of therapy may be 
directly involved in poor control in only 
39 (30.7%) of these cases. Nevertheless, the 
proportion of patients who were treated 
inadequately remains large, a matter that 
needs to be addressed. A likely explanation 
for inadequate escalation of therapy could 
be the fact that currently in the public 
sector, only one rheumatologist is serving 
the entire Free State and Northern Cape 
provinces. Owing to the vast number of 
patients attending this clinic, many patients 
will be seen by registrars and interns who 
may not escalate therapy as adequately as is 
required to ensure tight control.
It is therefore evident that the strongest 
association could be made between lack 
of treatment availability and poor disease 
control (directly or indirectly by preventing 
escalation of therapy), especially in the 
down-referral clinics. The importance of 
access to DMARD therapy for the control 
of RA is further supported by the fact 
that ~70% of the 34 patients who were 
controlled reported having received all of 
their medication. Although determining the 
reasons for poor drug availability was beyond 
the scope of this study, the reasons are likely 
to be multifactorial. After interviews with 
pharmacists, it appears that the following may 
be contributing to the situation: (i) problems 
with budget allocation in district as well as 
down-referral pharmacies; (ii) staff shortages 
in pharmacies (most notably in district units); 
and (iii) issues with delivery of medication. It 
has also been noted that many patients often 
attend pharmacies outside their designated 
area according to the down-referral protocol. 
As these drugs are sent to relevant peripheral 
pharmacies on a ‘per patient’ basis, patients 
who are not following the correct down-
referral channels will often not receive their 
medication. In situations where medication 
is not available at clinics, a patient will often 
be advised to return to their district hospital 
to receive their treatment. Two problems 
arise in these circumstances: firstly, these 
institutions often also do not have certain 
medications in stock, and secondly, access 
to transport is often problematic for many 
patients.
In this sample, the vast majority of 
patients reported good adherence to 
treatment. Furthermore, poor insight 
seemed to have played a negligible role in 
affecting disease control. A mere handful 
of patients reported problems relating to 
transport or administrative issues, and only 
5.6% reported that adverse effects affected 
their treatment regimen. The reported 
compliance appeared to be far better than 
suggested by the current literature.[14] 
This may have resulted from recall bias or 
inaccurate reporting by patients.
According to our data, 13.0% of patients 
had disease refractory to csDMARDs. The 
frequency of refractory disease may be far 
Data collected,
N=169 patients
n=163 patients
Data analysed,
n=161 patients
Excluded owing to 
incomplete information,
n=6 patients
Excluded owing to current 
or planned pregnancy,
n=2 patients
Fig. 1. Enrolment of participants. 
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higher, but it is likely that a large proportion of patients who were 
deemed to be poorly controlled for various reasons would in fact be 
found to have refractory disease once these factors were attended 
to. However, this could only be determined after excluding other 
possible causes for poor control, which would not be possible to 
achieve in the majority of these patients. In practice, identifying these 
patients is important because they may require escalation of therapy 
to bDMARDs according to national guidelines.[6] Biological agents 
are known to be highly effective in disease control, but owing to their 
cost, patients do not qualify until any reversible cause for poor control 
is addressed. A concerning finding was that of the 127 patients whose 
disease was not controlled, 71 (55.9%; 44.1% of the total sample) were 
in the high disease activity group. These patients are at high risk of 
debilitating disease, and attaining tighter control on an urgent basis 
should be a priority.
Most of the factors contributing to poor disease control are 
remediable, and measures should be taken to attempt to correct 
these issues as far as possible. Doctors should be trained in the 
importance of aggressive escalation of therapy. The addition of more 
rheumatologists or practitioners experienced in rheumatology into 
the system is likely to promote appropriate management. With regard 
to the lack of availability of medication at peripheral healthcare 
facilities, doctors and patients require a better understanding of the 
down-referral system and staffing issues need to be addressed. After 
this study was conducted, the dispensing protocol has been reviewed 
and a central chronic medicine dispensing and distribution unit has 
been implemented in Bloemfontein, which is expected to improve the 
availability of medication to patients in this area.
Study limitations and strengths
This study had some limitations. Like all validated disease activity 
scores, the CDAI is subject to inter-user variability. However, 
considerable efforts were employed to ensure accurate scores by 
means of training sessions and involvement of senior doctors with 
the assessments. In an ideal situation, data would have been collected 
by one doctor, specifically a rheumatologist. Unfortunately, in this 
setting it was not technically possible. However, the information sheet 
was clear and a substantial amount of information could be obtained 
from source notes.
Certain data obtained were dependent on the patient’s memory 
and therefore subject to recall bias, mostly involving the recollection 
of medication that the patient was not receiving from pharmacies. 
The majority of patients did not have their previous prescriptions 
available at the time of the interview. However, patients were assisted 
by means of visual and verbal memory aids when needed. Although 
a formal pill count would have been the ideal means of determining 
Table 2. Factors contributing to poor disease control among patients with rheumatoid arthritis on disease-modifying 
antirheumatic drugs*
Reported reasons for poor disease control
Total group  
(N=161), n (%)
Uncontrolled patients 
(N=127), n (%)
Controlled patients 
(N=34), n (%)
Insufficient treatment for disease state 72 (44.7) 72 (56.7) n/a
Dispensing issues 71 (44.1) 61 (48.0) 10 (29.4)
Insufficient treatment without dispensing concerns 39 (24.2) 39 (30.7) n/a
Side-effects 9 (5.6) 8 (6.3) 1 (2.9)
Administrative problems 7 (4.4) 7 (5.5) 0
Problems with transport/access to treatment facilities 1 (0.6) 1 (0.8) 0
Lack of compliance/insight 4 (2.5) 3 (2.4) 1 (2.9)
Refractory disease (no discernible cause for poor control) 21 (13.0) 21 (16.5) n/a
n/a = not applicable.
*More than one factor was applicable in some cases.
Table 1. Gender, ethnicity and degree of disease control of 
patients with rheumatoid arthritis on disease-modifying 
antirheumatic drugs (N=161)
n (%)
Gender
Female 138 (85.7)
Male 23 (14.3)
Ethnicity
Black African 131 (81.4)
Caucasian 21 (13.0)
Mixed race 7 (4.4)
Indian 2 (1.2
Degree of disease control
Remission (CDAI score ≤2.8) 5 (3.1)
Low disease activity (CDAI score 2.9 - 10) 29 (18.0)
Moderate disease activity (CDAI score 11 - 22) 56 (34.8)
High disease activity (CDAI score >22) 71 (44.1)
CDAI = Clinical Disease Activity Index.
Pa
tie
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s, 
%
100
80
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40
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Fig. 2. Percentage of patients who reported receiving all their disease-
modifying antirheumatic drugs (N=161).
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compliance, this was not feasible within the constraints of the study. 
The objective of the study in this regard was to determine to what 
degree poor DMARD availability was affecting disease control, 
and not which specific DMARDs were involved. A number of 
questionnaires were not clear as to which pharmacies were involved 
in dispensing, most notably regarding the step-down units. However, 
this did not affect the primary or secondary goals of the study.
Other confounders such as disease duration, baseline disease 
activity, erosive disease, seropositivity and acute-phase response were 
not taken into consideration in this study. Although these may play 
an important role in determining response to treatment and disease 
outcome, the study focused on identifying preventable factors, and 
the abovementioned confounders rather contribute to refractory 
disease. Further research is required to expand on the influence of 
these factors in this setting. The study also did not evaluate steroid use. 
Although a minority of patients end up on chronic steroid therapy, the 
use of these agents should be seen as ‘bridging therapy’ and not as a 
means to chronic disease control. Patients assessed in this study would 
have been on treatment for at least 6 months, allowing sufficient time 
for escalation of DMARD therapy and weaning off from steroids.[6]
To the authors’ knowledge, this study is the first to evaluate the 
degree of disease control in RA patients in the Free State. It has 
contributed to our understanding of how our patients are faring 
on conventional DMARD therapy, and what factors need to be 
addressed to enable better control in this resource-limited setting 
where biological agents are not readily available. Once these factors 
have been corrected as far as possible, follow-up studies should be 
conducted to determine the effect of good practice on disease control.
Conclusions
Disease control in our setting is currently suboptimal when compared 
with other available data. Many factors contribute to poor disease 
control, the major concern being lack of drug availability from 
pharmacies (particularly from peripheral units) and insufficient 
escalation of therapy by practitioners. Many of these issues can be 
alleviated, and measures should be taken to resolve these concerns 
as far possible.
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